Form 4: CervoMed Director Marwan Sabbagh Granted Stock Options Following Board Election

CervoMed Inc. director Marwan Sabbagh was granted options to purchase 8,100 shares of common stock as part of his compensation following his election to the board.

Summary

• Marwan Sabbagh, a director of CervoMed Inc. (CRVO), was granted an option to purchase 8,100 shares of the company's common stock.
• The grant occurred on June 23, 2025, in connection with his election to the Issuer's board of directors at its 2025 Annual Meeting of Stockholders.
• The stock option was issued under CervoMed's 2025 Equity Incentive Plan, consistent with the company's non-employee director compensation policy.
• The exercise price for the options is $6.52 per share.
• The shares underlying the award will vest on a monthly basis over a one-year period, in substantially equal 1/12th increments, beginning on June 30, 2025.
• Vesting is contingent upon Mr. Sabbagh's continued service through each applicable vesting date.
• The options have an expiration date of June 23, 2035.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects standard corporate governance and aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options to Director Marwan Sabbagh aligns his financial interests with those of the shareholders, encouraging long-term commitment and performance.
• The compensation structure is consistent with the company's established 2025 Equity Incentive Plan and non-employee director compensation policy, indicating structured corporate governance.

Future Outlook

The stock options granted to Director Sabbagh will vest monthly over a one-year period, contingent on his continued service, aligning his future compensation with the company's performance over this period.

Management Comments

• The grant was made 'in connection with the Reporting Person's election to the Issuer's board of directors at its 2025 Annual Meeting of Stockholders'.
• The grant was 'under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy'.

Industry Context

The granting of stock options to non-employee directors is a common practice in publicly traded companies, serving to align the interests of the board with those of the shareholders and to incentivize long-term value creation.

Comparison to Industry Standards

• The practice of granting equity-based compensation, such as stock options, to non-employee directors is a standard industry practice across various sectors, including biotechnology and pharmaceuticals, to attract and retain qualified board members.
• The vesting schedule over one year is also a common approach for director equity awards, promoting sustained engagement and oversight.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to more focused long-term value creation.
• Employees: No direct impact mentioned, but the equity incentive plan framework could apply to other employees.

Next Steps

• Marwan Sabbagh's continued service on the board of directors for the next year to ensure full vesting of the granted stock options.

Key Dates

Keywords

CervoMed Inc., CRVO, SEC Form 4, Stock Option Grant, Director Compensation, Equity Incentive Plan, Insider Transaction, Marwan Sabbagh